Recently, a survey conducted by Chinese disposable e-cigarette brand ELFBAR revealed that a batch of counterfeit disposable e-cigarette products are flooding the UK market. The source of the image is Vaporvoice.
Since June 2021, ELFBAR has conducted a campaign to combat counterfeiting. More than 120 manufacturers, including factories, warehouses, logistics companies, and foreign trade companies, have been targeted and raided. Over 2 million counterfeit ELFBAR products, as well as millions of packaging boxes, anti-counterfeiting codes, and half-finished smoking pipes and accessories, have been seized.
Victor Xiao, CEO of ELFBAR, stated that the criminals behind these counterfeit products have no concern for product safety or consumer health, and will stop at nothing to maximize their profits. While it may be difficult to distinguish between genuine and counterfeit products based solely on appearance, retailers can scan codes on the packaging to verify authenticity.
The General Secretary of the UK Vaping Industry Association, John Dunne, has warned that counterfeit electronic cigarettes pose a significant risk to the global reputation of the e-cigarette industry. Dunne has called for the introduction of a retail licensing scheme in the UK to prevent the sale of illegal products and to impose fines of at least £10,000 on retailers found to be breaking the law. He has also urged Chinese authorities to take strong action against those responsible for producing and selling counterfeit e-cigarettes to prevent such incidents from happening again.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
